AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $816 | -35.4% | 79,213 | +3.3% | 0.00% | -33.3% |
| Q2 2023 | $1,264 | +210.6% | 76,685 | +72.2% | 0.00% | +200.0% |
| Q1 2023 | $407 | +40.3% | 44,535 | +9.6% | 0.00% | 0.0% |
| Q4 2022 | $290 | -99.8% | 40,631 | +24.3% | 0.00% | – |
| Q3 2022 | $163,000 | +328.9% | 32,689 | +108.4% | 0.00% | – |
| Q2 2022 | $38,000 | -65.5% | 15,689 | -2.8% | 0.00% | – |
| Q1 2022 | $110,000 | -9.8% | 16,136 | +6.6% | 0.00% | – |
| Q4 2021 | $122,000 | -25.6% | 15,136 | -9.7% | 0.00% | – |
| Q3 2021 | $164,000 | +29.1% | 16,757 | -11.2% | 0.00% | – |
| Q2 2021 | $127,000 | -31.7% | 18,877 | -8.3% | 0.00% | -100.0% |
| Q1 2021 | $186,000 | +100.0% | 20,577 | +47.7% | 0.00% | – |
| Q4 2020 | $93,000 | +25.7% | 13,927 | -5.8% | 0.00% | – |
| Q3 2020 | $74,000 | -35.7% | 14,777 | +3.8% | 0.00% | – |
| Q2 2020 | $115,000 | – | 14,242 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 4,133,464 | $45,592,000 | 5.54% |
| Stonepine Capital Management, LLC | 747,863 | $8,249,000 | 4.45% |
| JW Asset Management, LLC | 444,439 | $4,902,000 | 3.12% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $40,320,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 1,150,000 | $12,685,000 | 1.62% |
| FALCON POINT CAPITAL, LLC | 855,101 | $9,432,000 | 1.27% |
| Perceptive Advisors | 1,429,114 | $15,763,000 | 0.79% |
| KNOTT DAVID M | 126,463 | $1,395,000 | 0.58% |
| HEARTLAND ADVISORS INC | 700,000 | $7,721,000 | 0.50% |
| Sio Capital Management, LLC | 91,413 | $1,008,000 | 0.48% |